AR110412A1 - Inhibidores de la cyp11a1 - Google Patents

Inhibidores de la cyp11a1

Info

Publication number
AR110412A1
AR110412A1 ARP170103609A ARP170103609A AR110412A1 AR 110412 A1 AR110412 A1 AR 110412A1 AR P170103609 A ARP170103609 A AR P170103609A AR P170103609 A ARP170103609 A AR P170103609A AR 110412 A1 AR110412 A1 AR 110412A1
Authority
AR
Argentina
Prior art keywords
alkyl
methyl
pyran
isoquinolinyl
dihydro
Prior art date
Application number
ARP170103609A
Other languages
English (en)
Spanish (es)
Inventor
Gerd Wohlfahrt
Matti Vaismaa
Eija Tiainen
Petteri Rummakko
Pekka Pietikinen
Mikko Passiniemi
Mikko Mkel
Belle David Din
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of AR110412A1 publication Critical patent/AR110412A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
ARP170103609A 2016-12-22 2017-12-20 Inhibidores de la cyp11a1 AR110412A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20166024 2016-12-22

Publications (1)

Publication Number Publication Date
AR110412A1 true AR110412A1 (es) 2019-03-27

Family

ID=61005837

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103609A AR110412A1 (es) 2016-12-22 2017-12-20 Inhibidores de la cyp11a1

Country Status (31)

Country Link
US (4) US10717726B2 (enExample)
EP (2) EP3558981B1 (enExample)
JP (2) JP7025432B2 (enExample)
KR (3) KR102491308B1 (enExample)
CN (1) CN110139861B (enExample)
AR (1) AR110412A1 (enExample)
AU (2) AU2017380282B2 (enExample)
CA (1) CA3047370A1 (enExample)
CL (1) CL2019001728A1 (enExample)
CO (1) CO2019007321A2 (enExample)
CY (1) CY1124461T1 (enExample)
DK (1) DK3558981T3 (enExample)
EA (1) EA039309B1 (enExample)
ES (1) ES2880151T3 (enExample)
HR (1) HRP20211255T1 (enExample)
HU (1) HUE056540T2 (enExample)
IL (2) IL267484B (enExample)
LT (1) LT3558981T (enExample)
MA (2) MA55983A (enExample)
MX (1) MX388538B (enExample)
NZ (1) NZ755395A (enExample)
PE (1) PE20191137A1 (enExample)
PH (1) PH12019550111A1 (enExample)
PL (1) PL3558981T3 (enExample)
PT (1) PT3558981T (enExample)
RS (1) RS62198B1 (enExample)
SI (1) SI3558981T1 (enExample)
TN (1) TN2019000189A1 (enExample)
TW (2) TWI762544B (enExample)
UA (1) UA124640C2 (enExample)
WO (1) WO2018115591A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110412A1 (es) * 2016-12-22 2019-03-27 Orion Corp Inhibidores de la cyp11a1
JP2023525137A (ja) * 2020-05-14 2023-06-14 オリオン コーポレーション Cyp11a1阻害剤
CA3200556A1 (en) * 2020-12-01 2021-11-30 David Din Belle 2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and similar compounds as cyp11a1 inhibitors for the treatment of prostate cancer
PE20231939A1 (es) * 2021-03-01 2023-12-05 Orion Corp Proceso para la preparacion de un inhibidor de cyp11a1 y sus intermedios
MX2023010269A (es) 2021-03-01 2023-11-14 Orion Corp Formas solidas de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona.
AR124985A1 (es) 2021-03-01 2023-05-24 Orion Corp Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona
US20240336603A1 (en) 2021-06-23 2024-10-10 Orion Corporation Process for the preparation of a cyp11a1 inhibitor and intermediates thereof
CN118076355A (zh) * 2021-09-28 2024-05-24 奥仁公司 用于治疗前列腺癌的cyp11a1抑制剂
EP4422755A1 (en) 2021-10-28 2024-09-04 Orion Corporation Salt forms of a 4h-pyran-4-one structured cyp11 at inhibitor
EP4430027A1 (en) 2021-11-10 2024-09-18 Orion Corporation Cyp11a1 inhibitors
JP2025502308A (ja) 2022-01-20 2025-01-24 オリオン・コーポレーション Cyp11a1阻害剤の医薬組成物
CN118307519A (zh) 2023-01-06 2024-07-09 上海闻耐医药科技有限公司 一类cyp11a1抑制剂化合物及其制备方法和用途
KR20240126916A (ko) 2023-02-14 2024-08-22 경북대학교 산학협력단 Asm 단백질 또는 이의 단편을 포함하는 퇴행성 신경질환 또는 우울증 예방 또는 치료용 조성물
CN121002012A (zh) * 2023-03-29 2025-11-21 西藏海思科制药有限公司 Cyp11a1抑制剂及其用途
CN121039123A (zh) * 2023-04-21 2025-11-28 西藏海思科制药有限公司 Cyp11a1抑制剂及其用途
AU2024270498A1 (en) * 2023-05-11 2025-11-27 Foshan Ionova Biotherapeutics Co., Inc. Novel compounds as cyp11a1 inhibitors and methods of use thereof
WO2025017072A1 (en) 2023-07-19 2025-01-23 Orion Corporation Stable pharmaceutical compositions of a cyp11a1 inhibitor
WO2025021182A1 (en) * 2023-07-27 2025-01-30 Acerand Therapeutics (Hong Kong) Limited Cyp11a1 inhibitors
WO2025051216A1 (zh) * 2023-09-08 2025-03-13 深圳众格生物科技有限公司 一种cyp11a1抑制剂、其制备方法及其应用
WO2025168117A1 (zh) * 2024-02-08 2025-08-14 盛睿泽华医药科技(苏州)有限公司 一种多环化合物及其制备方法和应用
WO2025237211A1 (zh) * 2024-05-11 2025-11-20 辽宁海思科制药有限公司 一种cyp11a1抑制剂的晶型物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6176485A (ja) * 1984-09-20 1986-04-18 Ss Pharmaceut Co Ltd 新規なγ−ピラン誘導体
US7344700B2 (en) * 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
EP1471063A1 (en) * 2003-02-28 2004-10-27 Exonhit Therapeutics S.A. Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis
US20140005181A1 (en) * 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
TW201534586A (zh) * 2013-06-11 2015-09-16 Orion Corp 新穎cyp17抑制劑/抗雄激素劑
AR110412A1 (es) * 2016-12-22 2019-03-27 Orion Corp Inhibidores de la cyp11a1

Also Published As

Publication number Publication date
TWI762544B (zh) 2022-05-01
WO2018115591A1 (en) 2018-06-28
US20200299280A1 (en) 2020-09-24
KR20230019496A (ko) 2023-02-08
IL267484A (en) 2019-08-29
TWI796205B (zh) 2023-03-11
KR102826021B1 (ko) 2025-06-30
EP3558981B1 (en) 2021-05-26
US20210347765A1 (en) 2021-11-11
EP3868756A1 (en) 2021-08-25
AU2021203497A1 (en) 2021-07-01
IL285729B (en) 2022-02-01
PT3558981T (pt) 2021-07-06
TN2019000189A1 (en) 2020-10-05
PL3558981T3 (pl) 2021-12-06
MX2019007373A (es) 2019-09-18
SI3558981T1 (sl) 2021-09-30
UA124640C2 (uk) 2021-10-20
US10717726B2 (en) 2020-07-21
JP2022078068A (ja) 2022-05-24
JP2020502229A (ja) 2020-01-23
EP3558981A1 (en) 2019-10-30
KR102491308B1 (ko) 2023-01-27
HUE056540T2 (hu) 2022-02-28
LT3558981T (lt) 2021-08-25
TW201835072A (zh) 2018-10-01
CN110139861B (zh) 2022-12-30
TW202229264A (zh) 2022-08-01
MA55983A (fr) 2022-03-23
US20190359601A1 (en) 2019-11-28
IL267484B (en) 2021-09-30
CY1124461T1 (el) 2022-07-22
KR20250097993A (ko) 2025-06-30
PH12019550111A1 (en) 2020-03-09
EA201991513A1 (ru) 2019-11-29
CA3047370A1 (en) 2018-06-28
MX388538B (es) 2025-03-20
US20240308989A1 (en) 2024-09-19
US11098032B2 (en) 2021-08-24
EA039309B1 (ru) 2022-01-12
JP7286825B2 (ja) 2023-06-05
CN110139861A (zh) 2019-08-16
CL2019001728A1 (es) 2019-09-27
RS62198B1 (sr) 2021-08-31
BR112019012906A2 (pt) 2019-12-03
US12030871B2 (en) 2024-07-09
MA47102B1 (fr) 2021-09-30
JP7025432B2 (ja) 2022-02-24
DK3558981T3 (da) 2021-07-26
IL285729A (en) 2021-09-30
NZ755395A (en) 2025-10-31
HRP20211255T1 (hr) 2021-11-12
AU2017380282A1 (en) 2019-08-01
PE20191137A1 (es) 2019-09-02
CO2019007321A2 (es) 2019-07-31
CN116162084A (zh) 2023-05-26
AU2017380282B2 (en) 2021-06-24
AU2021203497B2 (en) 2022-11-10
ES2880151T3 (es) 2021-11-23
KR20190095950A (ko) 2019-08-16

Similar Documents

Publication Publication Date Title
AR110412A1 (es) Inhibidores de la cyp11a1
AR122049A2 (es) Derivados de pirimidiniloxi benceno como herbicidas
AR112529A1 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos en el tratamiento de diversos tipos de cáncer
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR097633A1 (es) Pesticidas de azol bicíclico sustituido con heterociclos
AR089807A1 (es) Compuestos de imidazopirrolidinona
AR097403A1 (es) Derivados de benzamida como antagonistas de lpar1 y/o lpar5 y un proceso para su preparación
AR096643A1 (es) Procedimiento de síntesis para la preparación de análogos macrocíclicos c1-ceto de halicondrina b e intermediarios útiles en la misma incluyendo intermediarios que contienen grupos -so₂-(p-tolilo)
PE20150399A1 (es) Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR089051A1 (es) Compuestos de 2-(fenilo sustituido)-ciclopentan-1,3-diona y derivados de los mismos
AR100691A1 (es) Esteroides neuroactivos, composiciones, y usos de los mismos
AR104720A1 (es) Moduladores de ccr2
JP2017505762A5 (enExample)
AR062503A1 (es) Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor.
PE20150218A1 (es) Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
Srinivas et al. Synthesis and characterization of novel oxazines and demonstration that they specifically target cyclooxygenase 2
AR103265A1 (es) Compuestos de azolina sustituidos con un sistema de anillos condensado
EA201791816A1 (ru) Ингибиторы kv1.3 и их применение в медицине
AR082914A1 (es) Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos
EA202091120A2 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
AR085976A1 (es) Inhibidores de la poli(adp-ribosa)polimerasa (parp) para el tratamiento de neuropatia periferica inducida por un quimioterapia (cipn)
AR098492A1 (es) Derivados de purina
AR091261A1 (es) Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa
AR113346A1 (es) Derivados de picolinamida microbicidas
AR094272A1 (es) Compuestos de diona ciclica activos como herbicidas, o derivados de los mismos, sustituidos por un fenilo que tiene un sustituyente que contiene alquinilo

Legal Events

Date Code Title Description
FG Grant, registration